Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Altered Chemokine Receptor Expression in CD4<sup>+</sup> T Cells: A Signature of Visceral Leishmaniasis.

Parasite immunology·2026

Same author

Short-term β-lactam antibiotic exposure promotes peptidoglycan translocation to the brain and impairs functional connectivity and social recognition in mice.

Brain, behavior, and immunity·2025

Same author

The development and maintenance of immunity against visceral leishmaniasis.

Frontiers in immunology·2025

Same author

Liver X receptor unlinks intestinal regeneration and tumorigenesis.

Nature·2024

Same author

Passive immunization of mice with IgY anti-H5N1 protects against experimental influenza virus infection and allows development of protective immunity.

Vaccine·2024

Same author

Apolipoprotein E Is Upregulated in Blood and Circulating Monocytes of Indian Patients With Visceral Leishmaniasis.

Parasite immunology·2024

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Tracing immunity to human leishmaniasis.

Susanne Nylén¹, Hannah Akuffo

¹Department of Microbiology, Tumor Biology & Cell Biology, Karolinska Institute, Stockholm, Sweden. susanne.nylen@ki.se

Future Microbiology

|March 5, 2009

Summary

This summary is machine-generated.

Understanding immunological changes in leishmaniasis is key for developing effective vaccines and therapies. Identifying biomarkers can predict disease outcomes and streamline drug evaluation, aiding in the fight against leishmaniasis.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Related Experiment Videos

Last Updated: Jun 25, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Area of Science:

Immunology
Infectious Diseases
Vaccinology

Background:

Leishmaniasis recovery confers long-lasting immunity, yet understanding protective immunological changes is crucial for vaccine development.
Identifying reliable biomarkers for leishmaniasis is essential for efficient vaccine candidate screening and therapy evaluation.
Biomarkers can predict disease severity, patient outcomes, and aid in monitoring treatment efficacy, potentially reducing invasive procedures.

Purpose of the Study:

To discuss immunological changes associated with human leishmaniasis.
To highlight the value of immunological biomarkers in developing leishmaniasis vaccines.
To evaluate the role of biomarkers in assessing therapies for leishmaniasis.

Main Methods:

Review of immunological changes in various forms of human leishmaniasis.
Analysis of the utility of immunological biomarkers for vaccine development.
Assessment of biomarkers for therapeutic evaluation and prognosis in leishmaniasis.

Main Results:

Immunological shifts correlate with protection, susceptibility, and cure in leishmaniasis.
Biomarkers can serve as cost-effective tools for screening vaccine candidates.
Biomarkers offer prognostic value for disease severity and treatment response.

Conclusions:

Understanding leishmaniasis immunology is fundamental for vaccine and drug development.
Immunological biomarkers are vital for advancing leishmaniasis control strategies.
Biomarkers facilitate efficient evaluation of vaccines and therapies, improving patient outcomes.